CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting
CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting Testing cancer patients for PD-L1 mRNA levels using CIRCULOGENE technology can improve patient selection for tailored therapies and avoid unnecessary treatment-related toxicity. BIRMINGHAM, Ala. and Pensacola, Fla. (May 12, 2023) – CIRCULOGENE is an…
CIRCULOGENE’s blood-based, gene panel is central to research presented at last weekend’s Digestive Disease Week 2023
CIRCULOGENE’s blood-based, gene panel is central to research presented at last weekend’s Digestive Disease Week 2023 Speed of delivery resulting from liquid biopsy techniques was a key factor in the ability of circulating tumor DNA reports to inform decision making for first-line cancer therapy. BIRMINGHAM, Ala. and Pensacola, Fla. (May…
CIRCULOGENE Announces Appointment of Bob Gasparini to Board of Directors
BIRMINGHAM, Ala. and Pensacola, Fla. (December 8, 2022) – CIRCULOGENE is an innovative liquid biopsy company transforming precision medicine through the rapid and cost-effective delivery of actionable results and the only laboratory in the world that reports levels of the immunotherapy biomarker PD-L1 with a simple blood test. CIRCULOGENE is proud to announce…
CIRCULOGENE shares results of remarkable rectal cancer study
FOR IMMEDIATE RELEASE CIRCULOGENE shares results of remarkable rectal cancer study Identifying mismatch repair-deficient (MMRd) or microsatellite instability (MSI) BIRMINGHAM, Ala. and Pensacola, Fla. (June 27, 2022) – CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable biomarkers, shares remarkable results from a revolutionary immunotherapy…
CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium
FOR IMMEDIATE RELEASE CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium Liquid PD-L1 data demonstrates clinical utility in lung cancer patients BIRMINGHAM, Ala. and Pensacola, Fla. (December 2, 2021) – CIRCULOGENE, an innovative medical technology company transforming…
CIRCULOGENE Announces Lab Expansion in Florida
FOR IMMEDIATE RELEASE CIRCULOGENE Announces Lab Expansion in Florida Liquid Biopsy Company Laboratory Operations Are Growing in Pensacola BIRMINGHAM, Ala. and Pensacola, Fla. (October 14, 2021) – CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable results, and the only company in the world with a liquid…
CIRCULOGENE Announces Issuance of U.S. Patent for Method of Preparing Cell-Free Nucleic Acid Molecules by In Situ Amplification
Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples. BIRMINGHAM, Ala. – CIRCULOGENE, an innovative molecular diagnostics company transforming precision medicine through the rapid delivery of actionable results, announced today that the United States Patent and…
Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation
Current Trends in Clinical & Medical Sciences Chen Hsiung Yeh* Circulogene Theranostics, Birmingham, USA Received Date: January 24, 2020 Published Date: January 29, 2020 Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation Click here to download full pdf High-throughput sequencing of circulating cell-free DNA (cfDNA) as liquid biopsy has revolutionized tumor genome…
CIRCULOGENE – Subcontractor to U.S. Department of Defense Research Award – to Develop Liquid Biopsy Markers for Traumatic Brain Injury
$1.5 Million grant to The Geneva Foundation will use CIRCULOGENE’s liquid biopsy to quickly ID and accurately quantify organ-specific injury markers for improved treatment and survival in severely wounded military and civilian personnel. BIRMINGHAM, Ala.–(BUSINESS WIRE)– CIRCULOGENE molecular diagnostics laboratory, a subcontractor to The Geneva Foundation (Geneva), which has been awarded a $1.5 million…
CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation
BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part of CAP’s Accreditation Programs. The CAP accreditation – and the Clinical Laboratory Improvement Amendments (CLIA) certification…